 |
|
A Double-blind, Placebo-Controlled, Randomized Trial of Bupropion for Smoking Cessation in Primary Care
Roldano Fossati, MD;
Giovanni Apolone, MD;
Emanuele Negri, BA;
Anna Compagnoni, ScD;
Carlo La Vecchia, MD;
Simone Mangano, ScD;
Luca Clivio, ScD;
Silvio Garattini, MD; for the General Practice Tobacco Cessation Investigators Group
Arch Intern Med. 2007;167(16):1791-1797.
Background Studies undertaken in academic settings have shown that bupropion hydrochloride can double the odds of smoking cessation compared with placebo. To assess whether these results are applicable in primary care, we launched a double-blind, placebo-controlled, randomized trial to be conducted by general practitioners.
Methods We assigned 593 healthy smokers to receive bupropion hydrochloride, 150 mg twice a day, or placebo daily for 7 weeks (hereinafter, bupropion group [n = 400] and placebo group [n = 193], respectively). After the baseline visit, 4 clinical visits and 3 telephone calls were scheduled over the 1-year period. The primary end points were biochemically confirmed continuous abstinence at week 7 and at week 52.
Results Seventy-one Italian general practitioners enrolled participants from April 2004 to May 2005. Of the bupropion group, 41.0% were continuously abstinent from week 4 to week 7 compared with 22.3% of the placebo group (multivariate odds ratio, 2.37; 95% confidence interval, 1.60-3.53). The continuous abstinence rates from week 4 to week 52 were 25% in the bupropion group and 14% in the placebo group (odds ratio, 2.11; 95% confidence interval, 1.32-3.39). The mean weight gain was similar in both groups and among long-term abstainers was 3 kg in women and 4 kg in men. More participants in the bupropion group experienced an adverse event than those in the placebo group, but the percentage who discontinued use of the study medication was similar.
Conclusions Bupropion more than doubled the odds of continuous abstinence from smoking. The adherence of general practitioners and participants to the protocol was excellent, making our findings robust and easy to generalize to the context of primary care.
Author Affiliations: Mario Negri Institute for Pharmacologic Research (Drs Fossati, Apolone, Compagnoni, La Vecchia, Mangano, Clivio, and Garattini and Mr Negri) and Istituto di Statistica Medica e Biometria "G. A. Maccacaro," Università degli Studi di Milano (Dr La Vecchia), Milan, Italy.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey
Le Strat et al.
Tobacco Control 2011;20:338-343.
ABSTRACT
| FULL TEXT
Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review
Hughes et al.
Nicotine Tob Res 2010;12:756-762.
ABSTRACT
| FULL TEXT
Use of Pharmacotherapy for Smoking Cessation in Italy
Arch Intern Med 2009;169:1927-1928.
FULL TEXT
A smoking ban in public places increases the efficacy of bupropion and counseling on cessation outcomes at 1 year
Grassi et al.
Nicotine Tob Res 2009;11:1114-1121.
ABSTRACT
| FULL TEXT
Smoking cessation pharmacotherapy
Frishman
Ther Adv Cardiovasc Dis 2009;3:287-308.
ABSTRACT
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
Eisenberg et al.
CMAJ 2008;179:135-144.
ABSTRACT
| FULL TEXT
Bupropion helps primary care patients stop smoking
BMJ 2007;335:662-662.
ABSTRACT
| FULL TEXT
|
